MedTrace Logo

A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

NCT03795558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-03-23

No results posted yet for this study

Summary

This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.

Conditions

Interventions

DRUG

Etelcalcetide

Up-Titration

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Prim. Priv. Doz. Dr. Daniel Cejka

    lead OTHER

Principal Investigators

  • Daniel Cejka, Md · Head of Nephrology

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2021-12-21
Completion
2022-03-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03795558 on ClinicalTrials.gov